<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736515</url>
  </required_header>
  <id_info>
    <org_study_id>IC4-5702-205-CHN</org_study_id>
    <nct_id>NCT00736515</nct_id>
  </id_info>
  <brief_title>Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes</brief_title>
  <acronym>CODMS</acronym>
  <official_title>Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier (Tianjin) Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier (Tianjin) Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, with the further research of the pathogenesis of diabetes mellitus and the
      mechanism of oral antidiabetes drugs, the early combination therapy of oral antidiabetes
      drugs and insulin is getting paid more and more attention. A lot of studies have confirmed
      that Gliclazide MRs have excellent reducing blood glucose efficacy and vascular protection.
      Based on these theory and practice, this study is designed to demonstrate whether the
      combination therapy of Gliclazide MR and basal insulin can control the blood glycemia
      effectively and reduce the dosage of insulin and the hypoglycemia events compared to the
      premix insulin monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. Male or female with type 2 diabetes mellitus

        2. 35 years old≤age≤65 years old

        3. 19kg/m2≤BMI≤32kg/m2

        4. Uncontrolled blood glycemia (FPG≥7.0mmol/L and 7.5%&lt;HbA1c≤10%) after oral antidiabetes
           drugs treatment for more than 3 months

        5. Treated by diet controlling, 1 secretagogue agent and another oral antidiabetes drug,
           with the daily dosage of the secretagogue agent not more than 50% of its maximum

        6. Not participated in other clinical studies within the past 3 months

        7. Well know this study and sign the informed consent form

      Exclusion criteria:

        1. Unable to sign the informed consent form

        2. Treated by insulin, even transient usage within the past 1 year

        3. Type 1 diabetes mellitus

        4. Abnormal condition of gastrointestinal tract against the absorption of oral drugs

        5. Insufficient of liver and kidney function: ALT≥2.5 times of the upper limit of the
           normal value range and serum creatinine≥the upper limit of the normal value range

        6. Encountered the cardiovascular events such as the angina pectoris, myocardial
           infarction, severe ventricular arrhythmia, cerebral hemorrhage, cerebral infarction,
           heart failure ect. within the past half year

        7. Usage of the other hormone medicines such as cortical hormone, immunosuppressive agents
           or cytotoxic drugs within the past 2 months

        8. psychotic

        9. Allergic history to sulfonylurea drugs

       10. Diabetic coma or diabetic ketoacidosis

       11. In use of the miconazole

       12. Pregnancy or breeding women

      Primary endpoint:

      Decreasing value of FPG and HbA1c, Dosage of the insulin, Control rate of FPG

      Second Endpoints:

        1. MBG, SDBG, MAGE and MODD in the 48th CGMS

        2. Incidence of hypoglycemia and severe hypoglycemia

        3. Weight change
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MBG, SDBG, MAGE and MODD in the 48th CGMS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia and severe hypoglycemia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide MR and Insulin Glargine Injection</intervention_name>
    <description>Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Brand Name: Diamicron MR and Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biosynthetic Human Insulin Injection</intervention_name>
    <description>Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months</description>
    <arm_group_label>monotherapy</arm_group_label>
    <other_name>Brand Name: Novolin 30R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female with type 2 diabetes mellitus

          2. 35 years old≤age≤65 years old

          3. 19kg/m2≤BMI≤32kg/m2

          4. Uncontrolled blood glycemia (FPG≥7.0mmol/L and 7.5%&lt;HbA1c≤10%) after oral antidiabetes
             drugs treatment for more than 3 months

          5. Treated by diet controlling, 1 secretagogue agent and another oral antidiabetes drug,
             with the daily dosage of the secretagogue agent not more than 50% of its maximum

          6. Not participated in other clinical studies within the past 3 months

          7. Well know this study and sign the informed consent form

        Exclusion criteria:

          1. Unable to sign the informed consent form

          2. Treated by insulin, even transient usage within the past 1 year

          3. Type 1 diabetes mellitus

          4. Abnormal condition of gastrointestinal tract against the absorption of oral drugs

          5. Insufficient of liver and kidney function: ALT≥2.5 times of the upper limit of the
             normal value range and serum creatinine≥the upper limit of the normal value range

          6. Encountered the cardiovascular events such as the angina pectoris, myocardial
             infarction, severe ventricular arrhythmia, cerebral hemorrhage, cerebral infarction,
             heart failure ect. within the past half year

          7. Usage of the other hormone medicines such as cortical hormone, immunosuppressive
             agents or cytotoxic drugs within the past 2 months

          8. psychotic

          9. Allergic history to sulfonylurea drugs

         10. Diabetic coma or diabetic ketoacidosis

         11. In use of the miconazole

         12. Pregnancy or breeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Jia, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Zhou, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuqian Bao, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huazhang Yang, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Kuang, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hongmei Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haoming Tian, MD</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>SIR RUN RUN SHAW Hospital Affiliated to Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fenping Zheng, MD</last_name>
    <role>Study Director</role>
    <affiliation>SIR RUN RUN SHAW Hospital Affiliated to Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiang Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaohui Guo, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Gao, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muxun Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lixin Guo, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Ren, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIR RUN RUN SHAW Hospital Affiliated to Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005 Feb;28(2):254-9.</citation>
    <PMID>15677775</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>combination therapy,monotherapy,gliclazide MR,insulin,CGMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 4, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 22, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

